2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials …
Background Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term
outcomes of percutaneous coronary intervention after their complete bioresorption …
outcomes of percutaneous coronary intervention after their complete bioresorption …
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis
Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds
(BVS) offer the potential to improve long-term outcomes of percutaneous coronary …
(BVS) offer the potential to improve long-term outcomes of percutaneous coronary …
Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials
Background: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3
years after coronary artery implantation. The safety and effectiveness of BVS through this …
years after coronary artery implantation. The safety and effectiveness of BVS through this …
Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study
GW Stone, T Kimura, R Gao, DJ Kereiakes… - JAMA …, 2019 - jamanetwork.com
Importance Bioresorbable scaffolds were designed to provide clinical benefits after their
complete bioresorption. Prior studies demonstrated early risks with the Absorb polymeric …
complete bioresorption. Prior studies demonstrated early risks with the Absorb polymeric …
[PDF][PDF] Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the …
Aims: Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds
(BVS) in routine clinical practice are limited. To fill this gap, we report on the early and …
(BVS) in routine clinical practice are limited. To fill this gap, we report on the early and …
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
Background Previous studies showed more adverse events with coronary bioresorbable
vascular scaffolds (BVS) than with metallic drug-eluting stents (DES), although in one …
vascular scaffolds (BVS) than with metallic drug-eluting stents (DES), although in one …
A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease …
T Kimura, K Kozuma, K Tanabe… - European heart …, 2015 - academic.oup.com
Aims Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term
results compared with permanent metallic drug-eluting stents (DESs). However, whether …
results compared with permanent metallic drug-eluting stents (DESs). However, whether …
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials
Background Bioresorbable coronary stents might improve outcomes of patients treated with
percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular …
percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular …
Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial
DJ Kereiakes, SG Ellis, DC Metzger, RP Caputo… - Circulation, 2019 - Am Heart Assoc
Background: The Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) provides
early drug delivery and mechanical support similar to those of metallic drug-eluting stents …
early drug delivery and mechanical support similar to those of metallic drug-eluting stents …
3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial
DJ Kereiakes, SG Ellis, C Metzger, RP Caputo… - Journal of the American …, 2017 - jacc.org
Abstract Background: The Absorb everolimus-eluting poly-L-lactic acid–based
bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support …
bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support …